SCHEMBL4567208

SCHEMBL4567208

CO[C@H](C)CC(=O)O[C@H](C)CC(=O)O[C@H](C)CC(=O)OCC[C@@H](C)O

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.33
PRKCA P17252 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10047559 0.93 CYP19A1 (0.36) CYP19A1
SCHEMBL4567206 0.90 CYP19A1 (0.34) CYP19A1PRKCA
SCHEMBL17068925 0.90 PRKCA (0.33) CYP19A1PRKCA
SCHEMBL17068924 0.88 PRKCA (0.34) CYP19A1PRKCA
SCHEMBL20299549 0.79 CYP19A1 (0.36) CYP19A1PRKCA
SCHEMBL4567207 0.79 CYP19A1 (0.36) CYP19A1PRKCA
SCHEMBL13147621 0.78 CYP19A1 (0.40) CYP19A1
SCHEMBL21974553 0.78 CYP19A1 (0.40) CYP19A1
SCHEMBL22205224 0.78 CYP19A1 (0.40) CYP19A1
SCHEMBL22205226 0.78 CYP19A1 (0.40) CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180195096-A1 Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives UNIV OXFORD INNOVATION LTD (GB) 2018-07-12 US disclosed
US-20170196827-A1 Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation TDELTAS (GB) 2017-07-13 US disclosed
US-9579302-B2 Ketone bodies to protect tissues from damage by ionizing radiation TDELTAS (GB) 2017-02-28 US disclosed
US-20150250755-A1 KETONE BODIES TO PROTECT TISSUES FROM DAMAGE BY IONIZING RADIATION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) 2015-09-10 US disclosed
US-20120122978-A1 Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment ACCERA, INC. (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150250755-A1 KETONE BODIES TO PROTECT TISSUES FROM DAMAGE BY IONIZING RADIATION ACACB, BCKDK, ACACA CYP19A1 913/4885PRKCA 77/4885
US-20170196827-A1 Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation ACACB, BCKDK, ACACA CYP19A1 913/4885PRKCA 77/4885
US-20180195096-A1 Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives BCHE, LIPC, ACACB CYP19A1 386/4885PRKCA 932/4885
US-20120122978-A1 Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment CPT1B, ACADM, ACAA2 CYP19A1 2006/4885PRKCA 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.